Discover the full directors' dealings record of SeaSpine Holdings Corp, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, SeaSpine Holdings Corp has logged 83 reports. The latest transaction was reported on 1 July 2022 — J. Among the most active insiders: BRADLEY KEITH. The full history is openly available.
25 of 83 declarations
SeaSpine Holdings Corp. (ticker SPNE) was a US-based medical technology company that traded on the NASDAQ market in the United States. Prior to its merger with Orthofix Medical Inc., SeaSpine focused on spinal surgery, building a business around the design, development, and commercialization of surgical solutions for patients with spinal disorders. The company was headquartered in Carlsbad, California, positioning it within one of the key US medtech clusters for orthopedics and spine devices. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637761/000163776116000053/spne-2015123110xk.htm?utm_source=openai)) From an operating standpoint, SeaSpine developed a portfolio aimed at the spine surgery value chain. Its product set included spinal implants, biologics, and surgical navigation or procedural support tools. The business model was built to serve surgeons, hospitals, and specialty care facilities with an integrated offering rather than a single-product franchise. This made SeaSpine a focused player in a demanding segment where clinical adoption, product innovation, and surgeon relationships are critical to commercial success. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637761/000163776116000053/spne-2015123110xk.htm?utm_source=openai)) In competitive terms, SeaSpine operated in a crowded global market for spine and orthopedic medical devices, competing against much larger multinational manufacturers. Its strategic niche was its specialization in the spine category and its ability to combine hardware, biologics, and navigation into a broader procedural ecosystem. For investors, this type of profile typically offers exposure to procedure growth and innovation, but also implies high execution risk, pricing pressure, and a need for continuous product refresh. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884624/000095017023019721/ofix-20230331.htm?utm_source=openai)) The most significant recent corporate event was SeaSpine’s merger with Orthofix Medical Inc., which became effective on January 5, 2023. SEC filings state that the transaction was an all-stock merger of equals, creating a broader global spine and orthopedics company. As part of that deal, SeaSpine shareholders received Orthofix shares, and SeaSpine ceased to operate as an independent publicly traded issuer. The SEC Form 4 filings around that period also reflect insider ownership changes tied to the transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884624/000095017023019721/ofix-20230331.htm?utm_source=openai)) For French-speaking investors, the key takeaway is that SeaSpine was a US-listed NASDAQ medtech company with a specialized spine franchise, headquartered in Carlsbad, California, and focused on implants, biologics, and surgical navigation. Its standalone equity story ended with the January 2023 merger, after which its assets and operations were folded into Orthofix. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637761/000163776116000053/spne-2015123110xk.htm?utm_source=openai))